122643-81-6

Basic information

• Product Name: Ethanone, 1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
• Synonyms: Ethanone, 1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-;1-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1-ethanone
• CAS NO: 122643-81-6
• Molecular Formula: C₁₅H₁₂N₂O
• Molecular Weight: 236.27
• Mol File: 122643-81-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethanone, 1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(122643-81-6)
• EPA Substance Registry System: Ethanone, 1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(122643-81-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 122643-81-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Ethanone, 1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)is utilized as a compound of interest in pharmaceutical research and drug development due to its distinctive structural features and the potential for exhibiting a range of biological activities. Its exploration is driven by the possibility of it possessing pharmacological properties such as antioxidant, anti-inflammatory, or antimicrobial effects, which could be harnessed for the creation of novel therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Ethanone, 1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)is employed as a subject of study for its potential to contribute to the discovery of new drugs. Ethanone, 1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-'s unique structure and the possibility of it exhibiting beneficial pharmacological properties make it an attractive candidate for further investigation and development, with the aim of understanding its mechanisms of action and potential uses in treating various diseases and conditions.

Upstream product

• 56983-95-0 2-phenylpyrazolo[1,5-a]pyridine 
• 6295-87-0 N-aminopyridin-1-ium iodide 
• 122-57-6 1-Phenylbut-1-en-3-one 
• 1817-57-8 4-phenyl-3-butyne-2-one 
• 39996-41-3 1-aminopyridinium mesitylenesulphonate 

Downstream Products

• 131185-37-0 3-[2-(3-carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine 
• 131185-06-3 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo<1,5-a>pyridine 
• 131185-93-8 C₁₅H₁₁BrN₂O 
• 127717-42-4 1,3-bis(2-phenylpyrazolo<1,5-a>pyridi-3-yl)-1-butene 
• 127717-43-5 2-phenyl-3-vinylpyrazolo<1,5-a>pyridine 
• 127717-30-0 3-(1-hydroxyethyl)-2-phenylpyrazolo<1,5-a>pyridine 

Relevant articles and documents

Pilot-scale synthesis of a novel non-xanthine adenosine A1 receptor antagonist. 1,3-dipolar cycloaddition of pyridine N-imine to an acetylene

Adenosine A1 receptor antagonist, FK838, has been synthesized in 44% overall yield by a five-step sequence which is operationally straightforward and readily carried out on a large scale. Investigations into the 1,3-dipolar cycloaddition process that afforded a pyrazolo[1,5-a]pyridine derivative are also described. Process improvements and optimization of each step permitted elimination of column chromatography, resulting in a practical and cost-effective synthesis of FK838. These methods were successfully scaled up in a pharmaceutical pilot plant to give bulk drug used in clinical trials.

Synthesis of Functionalized Pyrazolo[1,5-a]pyridines: [3+2] Cycloaddition of N-Aminopyridines and α,β-Unsaturated Carbonyl Compounds/Alkenes at Room Temperature

The synthesis of functionalized pyrazolo[1,5-a]pyridines through oxidative [3+2] cycloaddition of N-aminopyridines with α,β-unsaturated carbonyl compounds or electron-withdrawing olefins is described. The reactions proceed in N-methylpyrrolidone as the solvent under metal-free conditions at room temperature.

Double (amino-sulfur generation of formic acid ) - 1,3-propane diester compound and its synthetic method, pharmaceutical composition and use thereof

The invention relates to a bis(aminodithioformate)-1,3-propane diester compound, and synthesis method thereof, a pharmaceutical composition containing the compound and a use, and especially relates to the use in preparing drugs for treating or preventing cancers. The compound is represented as the formula (I), wherein A is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, R1 and R2 are the same or different and are independently selected from hydrogen, alkyl, aryl alkyl or heteroaryl alkyl, or a substituted or unsubstituted heterocyclic ring formed together by the R1, the R2 and an N atom connected with the R1 and the R2.

Discovery and optimization of novel dual dithiocarbamates as potent anticancer agents

A series of dual dithiocarbamates were synthesized and evaluated for their in-vitro anticancer activities on human non-small cell lung cancer cell line H460. Nine compounds exhibited significant antiproliferative activities with IC50 less than 1 μM. Among them, compound 14m showed the highest inhibitory activity against H460 cell and inhibited the growth of nine types of tumor cells with IC50 values less than 1 μM. It also achieved IC50 of 54 nM and 23 nM against HepG2 and MCF-7 cell lines, respectively. Preliminary structure-activity relationship study indicated that: a) when the methyl group (region A) is substituted with benzene rings, ortho substitution on the benzene ring is favored for activity; b) substitution with heterocyclic structures at region A exhibited greater impact on the anti-tumor activity of compounds, in which pyridine ring, thiazole ring, coumarin and benzo[b]thiophene are favored and quinoline ring is the most favored; c) substitution with different amines (region B) also showed marked effect on the activity of compounds and dimethylamine and morpholine are preferred to other tested amines.

Multi-gram scale synthesis of FR180204

(Chemical Equation Presented) A concise synthesis of the ERK inhibitor FR180204 has been developed. The synthesis consists of six operationally simple steps and can be utilized to make multi-gram quantities of FR180204.

Novel heterocycle-substituted pyrimidines as inhibitors of NF-κB transcription regulation related to TNF-α cytokine release

Novel heterocyclic ring-substituted pyrimidines have been designed as inhibitors of glycogen synthase kinase-3β (GSK-3β) from the modification of known inhibitors. Several potent inhibitors exhibiting nanomolar activities were discovered against GSK-3β kinase as well as in an NF-κB reporter gene assay. Based on the results from in vitro TNF-α release inhibition and in vivo endotoxima, these inhibitors are expected to be useful candidates for treatment of inflammation-related diseases.

Method of treating kidney disease using pyrazolopyridine compound

The invention relates to a method for the treatment of renal toxicity, nephrosis or nephritis which comprises administering an effective amount of the pyrazolopyridine compounds of the invention.

Pharmaceutical method of treatment using pyrazolopyridine compound

The invention relates to a method for the treatment of ailments which comprises administering an effective amount of the pyrazolopyridine compounds of the invention.

Pyrazolopyridine compound and processes for preparation thereof

The disclosure deals with pyrazolopyridine compounds of the formula STR1 wherein the variables are defined in the specification. The compounds are useful in the treatment of bronchial asthma, immunosuppression, diabetes, etc.

Pharmaceutically useful pyrazolopyridines

The disclosure deals with a pyrazolopyridine compound of the formula STR1 wherein the variables are defined in the specification. The compounds are useful as a diuretic, antihypertensive agent, etc.